replimune group inc - REPL
REPL
Close Chg Chg %
9.72 0.37 3.81%
Closed Market
10.09
+0.37 (3.81%)
Volume: 606.97K
Last Updated:
Dec 24, 2025, 1:00 PM EDT
Company Overview: replimune group inc - REPL
REPL Key Data
| Open $9.95 | Day Range 9.84 - 10.27 |
| 52 Week Range 2.68 - 14.80 | Market Cap $762.47M |
| Shares Outstanding 78.44M | Public Float 71.82M |
| Beta 0.67 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.61 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.54M |
REPL Performance
| 1 Week | 2.13% | ||
| 1 Month | 0.90% | ||
| 3 Months | 144.31% | ||
| 1 Year | -17.70% | ||
| 5 Years | -75.90% |
REPL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About replimune group inc - REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
REPL At a Glance
Replimune Group, Inc.
500 Unicorn Park Drive
Woburn, Massachusetts 01801
| Phone | 1-781-222-9600 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -247,297,000.00 | |
| Sector | Health Technology | Employees | 479 | |
| Fiscal Year-end | 03 / 2026 | |||
| View SEC Filings |
REPL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.807 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.454 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.202 |
REPL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -516,277.662 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
REPL Liquidity
| Current Ratio | 7.952 |
| Quick Ratio | 7.952 |
| Cash Ratio | 7.758 |
REPL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -47.601 |
| Return on Equity | -62.579 |
| Return on Total Capital | -50.263 |
| Return on Invested Capital | -52.925 |
REPL Capital Structure
| Total Debt to Total Equity | 18.316 |
| Total Debt to Total Capital | 15.48 |
| Total Debt to Total Assets | 13.815 |
| Long-Term Debt to Equity | 17.358 |
| Long-Term Debt to Total Capital | 14.671 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Replimune Group Inc - REPL
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 4.58M | 2.45M | 2.65M | 3.50M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.58M | 2.45M | 2.65M | 3.50M | |
Depreciation
| 4.58M | 2.45M | 2.65M | 3.50M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +10.53% | -46.51% | +8.50% | +31.90% | |
Gross Income
| (4.58M) | (2.45M) | (2.65M) | (3.50M) | |
Gross Income Growth
| -10.53% | +46.51% | -8.50% | -31.90% | |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 116.91M | 177.55M | 234.04M | 259.90M | |
Research & Development
| 80.64M | 129.44M | 176.88M | 191.22M | |
Other SG&A
| 36.26M | 48.11M | 57.16M | 68.68M | |
SGA Growth
| +48.70% | +51.87% | +31.82% | +11.05% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (121.48M) | (179.99M) | (236.69M) | (263.40M) | |
Non Operating Income/Expense
| 2.50M | 7.24M | 26.05M | 22.69M | |
Non-Operating Interest Income
| 390.00K | 10.01M | 23.36M | 21.12M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 2.22M | 4.16M | 6.66M | 7.89M | |
Interest Expense Growth
| -27.35% | +87.13% | +60.10% | +18.51% | |
Gross Interest Expense
| 2.22M | 4.16M | 6.66M | 7.89M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (121.21M) | (176.91M) | (217.31M) | (248.60M) | |
Pretax Income Growth
| -44.85% | -45.96% | -22.83% | -14.40% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| (3.17M) | (2.63M) | (1.51M) | (1.30M) | |
Income Tax - Current - Domestic
| - | 288.00K | 408.00K | 468.00K | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| 3.17M | 2.91M | 1.92M | 1.77M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (118.04M) | (174.28M) | (215.79M) | (247.30M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (118.04M) | (174.28M) | (215.79M) | (247.30M) | |
Net Income Growth
| -45.96% | -47.65% | -23.82% | -14.60% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (118.04M) | (174.28M) | (215.79M) | (247.30M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (118.04M) | (174.28M) | (215.79M) | (247.30M) | |
EPS (Basic)
| -2.2607 | -2.9939 | -3.2416 | -3.0696 | |
EPS (Basic) Growth
| -29.29% | -32.43% | -8.27% | +5.31% | |
Basic Shares Outstanding
| 52.21M | 58.21M | 66.57M | 80.56M | |
EPS (Diluted)
| -2.2607 | -2.9939 | -3.2416 | -3.0696 | |
EPS (Diluted) Growth
| -29.29% | -32.43% | -8.27% | +5.31% | |
Diluted Shares Outstanding
| 52.21M | 58.21M | 66.57M | 80.56M | |
EBITDA
| (116.91M) | (177.55M) | (234.04M) | (259.90M) | |
EBITDA Growth
| -48.70% | -51.87% | -31.82% | -11.05% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 12.714 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.764 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -3.205 | |
| Last Quarter’s Earnings | -0.90 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.07 | Next Fiscal Year Estimate | -2.123 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 8 | 6 |
| Mean Estimate | -0.76 | -0.74 | -3.21 | -2.12 |
| High Estimates | -0.52 | -0.52 | -2.50 | -1.59 |
| Low Estimate | -0.93 | -0.95 | -3.73 | -2.86 |
| Coefficient of Variance | -17.66 | -19.76 | -14.53 | -23.86 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 2 |
| MEAN | Overweight | Overweight | Hold |
SEC Filings for Replimune Group Inc - REPL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Replimune Group Inc - REPL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 12, 2025 | Kapil Dhingra Director | 3,169 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.75 per share | 5,545.75 |
| Dec 12, 2025 | Kapil Dhingra Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.4 per share | 0.00 |
| Dec 12, 2025 | Kapil Dhingra Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Dieter Weinand Director | 32,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Veleka R. Peeples-Dyer Director | 32,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Andrew Schwendenman Chief Accounting Officer | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Andrew Schwendenman Chief Accounting Officer | 71,571 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Christopher Sarchi Chief Commercial Officer | 67,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Christopher Sarchi Chief Commercial Officer | 132,045 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Konstantinos Xynos Chief Medical Officer | 67,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Konstantinos Xynos Chief Medical Officer | 154,885 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Sushil Patel Chief Executive Officer; Director | 250,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Sushil Patel Chief Executive Officer; Director | 368,681 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Paolo Pucci Director | 32,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Christy J. Oliger Director | 32,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Madhavan Balachandran Director | 32,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Emily Hill Chief Financial Officer | 67,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Emily Hill Chief Financial Officer | 146,057 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Joseph P. Slattery Director | 32,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |